Traveller vaccination rubella: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Traveller vaccination human papillomavirus}}
{{Traveller vaccination rubella}}
{{CMG}};{{AE}}{{MehdiP}}
{{CMG}};{{AE}}{{USAMA}}
==Overview==
==Overview==
Protection against rubella is not specific to the needs of travellers. In most countries rubella vaccine is routinely administered in childhood. Missing rubella vaccinations in travellers should be offered according to national recommendations.
Protection against rubella is not specific to the needs of travellers. In most countries rubella vaccine is routinely administered in childhood. Missing rubella vaccinations in travellers should be offered according to national recommendations.

Revision as of 16:39, 20 April 2017

Template:Traveller vaccination rubella Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]

Overview

Protection against rubella is not specific to the needs of travellers. In most countries rubella vaccine is routinely administered in childhood. Missing rubella vaccinations in travellers should be offered according to national recommendations.

Disease cause

Rubella virus.

Transmission

Primarily by airborne respiratory droplets.

Nature of the disease

Rubella is usually a mild childhood disease characterized by moderate fever, lymphadenopathy and a rash. In adults, transient arthralgia and arthritis may occur. Rubella infection in early pregnancy often results in miscarriage, stillbirth or multiple fetal defects (congenital rubella syndrome).

Geographical distribution

Worldwide, but incidence depends on coverage of rubella vaccination.

Risk for travellers

Non-immune travellers may be at risk when visiting countries with insufficient vaccination coverage. Particular attention should be paid to ensuring protection of women in early pregnancy or who may become pregnant during the period of travel.

Vaccine

Live attenuated vaccine: available either in monovalent form (rubella component only) or in fixed combinations with one or more of vaccines against mumps, measles and varicella. Two intramuscular doses are administered at an interval of at least four weeks